^
Association details:
| Biomarker: | ERBB3 expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Betalutin (177Lu-satetraxetan-lilotomab) (Ionizing radiation emitter, CD37 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5040 / 7 - Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors
Published date:
03/15/2023
Excerpt:
Here we evaluated the antitumor effects of 225Ac or 177Lu armed HER3 ARCs across multiple HER3-expressing cancer models such as ovarian, colorectal, prostate, and renal cancer....HER3 ARCs induced cytotoxicity and inhibited colony formation of HER3-positive tumor cell lines. Significant in vivo human tumor xenograft growth inhibition was observed in response to 225Ac or 177Lu HER3 ARCs...In this study, both 225Ac-HER3 ARC and 177Lu-HER3 ARC demonstrated significant antitumor activity against HER3-expressing tumors in a dose-dependent manner.
